Published in Virology on August 15, 2011
The non-human primate model of tuberculosis. J Med Primatol (2012) 1.37
Simian hemorrhagic fever virus infection of rhesus macaques as a model of viral hemorrhagic fever: clinical characterization and risk factors for severe disease. Virology (2011) 1.07
Emergence of cowpox: study of the virulence of clinical strains and evaluation of antivirals. PLoS One (2013) 0.97
Intrabronchial inoculation of cynomolgus macaques with cowpox virus. J Gen Virol (2011) 0.81
Comparison of host cell gene expression in cowpox, monkeypox or vaccinia virus-infected cells reveals virus-specific regulation of immune response genes. Virol J (2013) 0.78
Poxvirus antigen staining of immune cells as a biomarker to predict disease outcome in monkeypox and cowpox virus infection in non-human primates. PLoS One (2013) 0.78
Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humans. Antimicrob Agents Chemother (2012) 0.75
Small particle aerosol inoculation of cowpox Brighton Red in rhesus monkeys results in a severe respiratory disease. Virology (2015) 0.75
Development of a preventive vaccine for Ebola virus infection in primates. Nature (2000) 8.32
Human asymptomatic Ebola infection and strong inflammatory response. Lancet (2000) 5.20
Poxviruses and immune evasion. Annu Rev Immunol (2001) 4.80
Chemokines in the pathogenesis of vascular disease. Circ Res (2004) 4.64
Exotic emerging viral diseases: progress and challenges. Nat Med (2004) 4.54
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature (2004) 3.65
Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med (2005) 3.19
Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J Virol (2004) 2.72
The Pathological Anatomy and Histology of Variola. J Med Res (1904) 2.70
Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A (2010) 2.69
Poxvirus genomes: a phylogenetic analysis. J Gen Virol (2004) 2.40
The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab Invest (2001) 2.38
Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology (2005) 2.36
Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc Natl Acad Sci U S A (2004) 2.36
A tale of two clades: monkeypox viruses. J Gen Virol (2005) 2.24
Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis (2010) 2.24
Breaking the deadlock over destruction of the smallpox virus stocks. Biosecur Bioterror (2011) 2.21
Human cowpox 1969-93: a review based on 54 cases. Br J Dermatol (1994) 2.19
Human monkeypox: an emerging zoonotic disease. Future Microbiol (2007) 2.15
Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J Virol (2005) 2.11
Inflammation and coagulation. Crit Care Med (2010) 2.11
Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine (2001) 2.06
Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am J Trop Med Hyg (2007) 1.86
Cowpox virus infection: an emerging health threat. Curr Opin Infect Dis (2008) 1.85
Cytokine and chemokine expression in humans infected with Sudan Ebola virus. J Infect Dis (2007) 1.63
Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob Agents Chemother (2009) 1.52
Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature (2005) 1.51
The morbid anatomy of smallpox. Doc Med Geogr Trop (1952) 1.47
Poxvirus Bioinformatics Resource Center: a comprehensive Poxviridae informational and analytical resource. Nucleic Acids Res (2005) 1.47
ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob Agents Chemother (2009) 1.45
Human monkeypox: clinical features of 282 patients. J Infect Dis (1987) 1.44
Real-time PCR assay to detect smallpox virus. J Clin Microbiol (2003) 1.32
Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc Natl Acad Sci U S A (2008) 1.31
Animal models of orthopoxvirus infection. Vet Pathol (2010) 1.29
Comparative analysis of monkeypox virus infection of cynomolgus macaques by the intravenous or intrabronchial inoculation route. J Virol (2010) 1.25
Monkeypox virus detection in rodents using real-time 3'-minor groove binder TaqMan assays on the Roche LightCycler. Lab Invest (2004) 1.23
Crosstalk between coagulation and inflammation during Dengue virus infection. Thromb Haemost (2008) 1.21
Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge. J Infect Dis (2005) 1.17
Human monkeypox: secondary attack rates. Bull World Health Organ (1988) 1.15
Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J Immunol (1998) 1.12
A novel highly reproducible and lethal nonhuman primate model for orthopox virus infection. PLoS One (2010) 1.11
A novel respiratory model of infection with monkeypox virus in cynomolgus macaques. J Virol (2011) 1.11
Cowpox virus transmission from rats to monkeys, the Netherlands. Emerg Infect Dis (2006) 1.10
The cause of death in smallpox: an examination of the pathology record. Mil Med (2002) 1.09
Haemorrhagic smallpox. J Hyg (Lond) (1969) 1.09
Countermeasures to the bioterrorist threat of smallpox. Curr Mol Med (2005) 1.08
Human monkeypox. J Hyg Epidemiol Microbiol Immunol (1983) 1.07
Differential pathogenesis of cowpox virus intranasal infections in mice induced by low and high inoculum volumes and effects of cidofovir treatment. Int J Antimicrob Agents (2008) 1.05
Killing a killer: what next for smallpox? PLoS Pathog (2010) 0.99
Fatal poxvirus outbreak in a colony of New World monkeys. Vet Pathol (2006) 0.97
Virulence and pathophysiology of the Congo Basin and West African strains of monkeypox virus in non-human primates. J Gen Virol (2009) 0.96
HAEMORRHAGIC SMALLPOX: A STUDY OF 240 CASES. J Indian Med Assoc (1964) 0.94
Stochastic model for interhuman spread of monkeypox. Am J Epidemiol (1987) 0.94
Looking back at smallpox. Clin Infect Dis (2004) 0.92
Purpura variolosa; its manifestations in skin and blood. Yale J Biol Med (1952) 0.90
Genome-based phylogeny of poxvirus. Intervirology (2006) 0.90
Haemorrhagic smallpox. I. Preliminary haematological studies. Bull World Health Organ (1965) 0.86
Haemorrhagic smallpox. 2. Specific bleeding and coagulation studies. Bull World Health Organ (1965) 0.85
Laboratory testing in disseminated intravascular coagulation. Semin Thromb Hemost (2010) 0.82
Why not destroy the remaining smallpox virus stocks? Vaccine (2011) 0.78
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med (2005) 6.77
Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA (2002) 6.59
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature (2003) 6.35
Prospects for a dengue virus vaccine. Nat Rev Microbiol (2007) 4.99
The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol (2003) 4.73
Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol (2003) 4.67
Exotic emerging viral diseases: progress and challenges. Nat Med (2004) 4.54
First-trimester screening for trisomies 21 and 18. N Engl J Med (2003) 4.47
Ovarian tumor domain-containing viral proteases evade ubiquitin- and ISG15-dependent innate immune responses. Cell Host Microbe (2007) 4.14
Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol (2010) 3.77
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature (2004) 3.65
Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet (2003) 3.57
Panmicrobial oligonucleotide array for diagnosis of infectious diseases. Emerg Infect Dis (2007) 3.51
Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis (2003) 3.33
Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet (2006) 3.15
Overlapping motifs (PTAP and PPEY) within the Ebola virus VP40 protein function independently as late budding domains: involvement of host proteins TSG101 and VPS-4. J Virol (2003) 3.05
Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A (2003) 2.82
Development of a new vaccine for the prevention of Lassa fever. PLoS Med (2005) 2.71
Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol (2003) 2.66
Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog (2007) 2.64
Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med (2006) 2.64
Evaluation of perceived threat differences posed by filovirus variants. Biosecur Bioterror (2011) 2.62
rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis (2005) 2.46
Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis (2007) 2.44
Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology (2005) 2.36
Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol (2002) 2.31
Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis (2002) 2.26
Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology (2005) 2.25
Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis (2006) 2.19
Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog (2010) 2.18
Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog (2008) 2.10
Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett (2002) 2.06
Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol (2011) 1.99
The host response to smallpox: analysis of the gene expression program in peripheral blood cells in a nonhuman primate model. Proc Natl Acad Sci U S A (2004) 1.85
CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med (2011) 1.83
Clinical use of array comparative genomic hybridization (aCGH) for prenatal diagnosis in 300 cases. Prenat Diagn (2009) 1.78
Smallpox and pan-orthopox virus detection by real-time 3'-minor groove binder TaqMan assays on the roche LightCycler and the Cepheid smart Cycler platforms. J Clin Microbiol (2004) 1.77
Framework for leadership and training of Biosafety Level 4 laboratory workers. Emerg Infect Dis (2008) 1.66
Use of the Learning Curve-Cumulative Summation test for quantitative and individualized assessment of competency of a surgical procedure in obstetrics and gynecology: fetoscopic laser ablation as a model. Am J Obstet Gynecol (2010) 1.63
Biochemical and functional characterization of the Ebola virus VP24 protein: implications for a role in virus assembly and budding. J Virol (2003) 1.60
Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Arch Virol (2012) 1.59
Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques. Viral Immunol (2004) 1.55
Sequential pathways of testing after first-trimester screening for trisomy 21. Obstet Gynecol (2004) 1.53
Pathologic findings associated with delayed death in nonhuman primates experimentally infected with Zaire Ebola virus. J Infect Dis (2007) 1.52
A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4. Virology (2003) 1.51
A randomized trial of amnioreduction versus septostomy in the treatment of twin-twin transfusion syndrome. Am J Obstet Gynecol (2005) 1.48
Trigger events: enviroclimatic coupling of Ebola hemorrhagic fever outbreaks. Am J Trop Med Hyg (2004) 1.45
The soy isoflavone genistein decreases adipose deposition in mice. Endocrinology (2003) 1.43
Cynomolgus macaque as an animal model for severe acute respiratory syndrome. PLoS Med (2006) 1.40
Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection. Virology (2003) 1.40
Estimation of time of fetal death in the second trimester by placental histopathological examination. Pediatr Dev Pathol (2003) 1.40
Management of intermittent exotropia. J Pediatr Ophthalmol Strabismus (2002) 1.38
rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults. Hum Vaccin (2006) 1.36
The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Hum Vaccin (2006) 1.35
MassTag polymerase chain reaction for differential diagnosis of viral hemorrhagic fever. Emerg Infect Dis (2006) 1.35
Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1. J Virol (2004) 1.34
Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes. J Virol (2002) 1.32
Real-time PCR assay to detect smallpox virus. J Clin Microbiol (2003) 1.32
Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. Am J Trop Med Hyg (2008) 1.28
Ebola virus genome plasticity as a marker of its passaging history: a comparison of in vitro passaging to non-human primate infection. PLoS One (2012) 1.28
Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines. J Virol (2006) 1.28
Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J Infect Dis (2012) 1.27
Clinical management of filovirus-infected patients. Viruses (2012) 1.26
Comparative analysis of monkeypox virus infection of cynomolgus macaques by the intravenous or intrabronchial inoculation route. J Virol (2010) 1.25
Clarification and guidance on the proper usage of virus and virus species names. Arch Virol (2010) 1.20
Smallpox research activities: U.S. interagency collaboration, 2001. Emerg Infect Dis (2002) 1.20
Projected mesothelioma incidence in men in New South Wales. Occup Environ Med (2007) 1.20
The temporal program of peripheral blood gene expression in the response of nonhuman primates to Ebola hemorrhagic fever. Genome Biol (2007) 1.20
Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol (2004) 1.19
Towards a vaccine against Ebola virus. Expert Rev Vaccines (2003) 1.19
Cellular localization and antigenic characterization of crimean-congo hemorrhagic fever virus glycoproteins. J Virol (2005) 1.19
Viral hemorrhagic fevers. Clin Lab Med (2006) 1.18
A proposal to change existing virus species names to non-Latinized binomials. Arch Virol (2010) 1.18
Experimental therapy of filovirus infections. Antiviral Res (2002) 1.16
Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae. Arch Virol (2013) 1.16
Lymphocyte death in a mouse model of Ebola virus infection. J Infect Dis (2007) 1.12
A novel respiratory model of infection with monkeypox virus in cynomolgus macaques. J Virol (2011) 1.11
Pre-eclampsia and expression of heparin-binding EGF-like growth factor. Lancet (2002) 1.11
Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers. Am J Trop Med Hyg (2009) 1.11
Potential impact of a 2-person security rule on BioSafety Level 4 laboratory workers. Emerg Infect Dis (2009) 1.11
Crimean-Congo hemorrhagic fever: current and future prospects of vaccines and therapies. Antiviral Res (2011) 1.11
4-1BB co-stimulation enhances human CD8(+) T cell priming by augmenting the proliferation and survival of effector CD8(+) T cells. Int Immunol (2002) 1.10
Identification of a novel C-terminal cleavage of Crimean-Congo hemorrhagic fever virus PreGN that leads to generation of an NSM protein. J Virol (2007) 1.10
Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Arch Virol (2013) 1.10
Taxonomic reorganization of the family Bornaviridae. Arch Virol (2014) 1.09
Effects of soy isoflavones and conjugated equine estrogens on inflammatory markers in atherosclerotic, ovariectomized monkeys. J Clin Endocrinol Metab (2004) 1.08
Evaluation of monkeypox disease progression by molecular imaging. J Infect Dis (2011) 1.07
Simian hemorrhagic fever virus infection of rhesus macaques as a model of viral hemorrhagic fever: clinical characterization and risk factors for severe disease. Virology (2011) 1.07